普拉克索联合左旋多巴治疗帕金森病疗效及安全性研究

Efficacy and safety of pramipexole combined with levodopa in Parkinson's disease

目的探讨普拉克索联合左旋多巴治疗帕金森病(PD)的疗效及安全性。方法选取2014年2月至2016年2月收治的PD患者134例,随机分为观察组(n=67)与对照组(n=67)。对照组单用左旋多巴片治疗,观察组予普拉克索和左旋多巴联合治疗。采用统一PD评分量表(UPDRS)评价治疗后症状,汉密顿抑郁量表17项(HAMD-17)评价抑郁状态。比较两组患者治疗后症状、抑郁状态及不良反应情况。结果与治疗前比较,两组患者治疗后UPDRS评分、HAMD-17评分均明显下降,差异有统计学意义(P<0.01);观察组UPDRS评分、HAMD-17评分明显低于对照组,差异有统计学意义(P<0.01)。两组患者不良反应发生率比较,观察组(7.46%)明显低于对照组(17.91%),差异有统计学意义(P<0.05)。结论普拉克索联合左旋多巴治疗PD的临床疗效确切,安全性高,值得临床进一步规范应用。

Objective To investigate the effectiveness and safety of pramipexole combined with levodopa in the treatment of Parkinson＇s disease（ PD）. Methods A total of 134 cases of PD patients were selected from February 2014 to February 2016. Patients were randomly divided into the observation group（ n = 67） and the control group（ n = 67）. Patients in the control group were treated with single levodopa,and the others in the observation group were treated with pramipexole combined with levodopa. Using the unified PD rating scale（ UPDRS） evaluation of symptoms after treatment,Hamilton depression scale 17 items（ HAMD-17） to evaluate depressive state. Patients in the two groups after treatment were compared with symptoms,depression and adverse reactions. Results After the treatment,UPDRS score,HAMD-17 score were significantly reduced in both groups（ P〈0. 01）; UPDRS score and HAMD-17 score in the observation group was significantly lower than those in the control group（ P〈0. 01）. The adverse reaction rate in the observation group（ 7. 46%） was significantly lower than that in the control group（ 17. 91%）,and the difference was statistically significant（ P〈0. 05）. Conclusion Pramipexole combined with levodopa has effective clinical efficacy,high safety in the treatment of PD,and is worthy of further standard clinical application.